









Markets
/
Stocks
/
nasdaq-inmb
/

INmune Bio Inc

INMB

1.510USD

+0.090+6.34%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

40.14MMarket Cap

LossP/E TTM



INmune Bio Inc

1.510

+0.090+6.34%

Overview Financials Analysis Company

Overview

Financials

Analysis

Company

More Details of INmune Bio Inc Company

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

INmune Bio Inc Info



Ticker SymbolINMB

Company nameINmune Bio Inc

IPO dateFeb 04, 2019

CEOMoss (David J)

Number of employees22

Security typeOrdinary Share

Fiscal year-endFeb 04

Address225 Ne Mizner Blvd, Suite 640

CityBOCA RATON

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code33432

Phone18589643720

Websitehttps://www.inmunebio.com/

Ticker SymbolINMB

IPO dateFeb 04, 2019

CEOMoss (David J)

Company Executives of INmune Bio Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Scott Juda, J.D.

Independent Director

71.60K

Mr. David J. Moss

President, Chief Executive Officer

Prof. Mark Lowdell, Ph.D.

Chief Scientific Officer

Mr. J. Kelly Ganjei

Independent Director

Mr. Timothy (Tim) Schroeder

Independent Director

Ms. Marcia Allen

Independent Director

Mr. Cory Ellspermann

Chief Financial Officer

Name

Name/Position

Position

Shareholding

Change

Mr. Scott Juda, J.D.

Independent Director

71.60K

Mr. David J. Moss

President, Chief Executive Officer

Prof. Mark Lowdell, Ph.D.

Chief Scientific Officer

Mr. J. Kelly Ganjei

Independent Director

Mr. Timothy (Tim) Schroeder

Independent Director

Ms. Marcia Allen

Independent Director

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sun, Nov 16

Shareholders

Shareholder Types

Shareholders

Proportion

Tesi (Raymond Joseph)

5.85%

Lowdell (Mark William)

5.68%

Moss (David J.)

4.84%

BlackRock Institutional Trust Company, N.A.

4.15%

The Vanguard Group, Inc.

3.60%

Other

75.89%

Shareholders

Proportion

Tesi (Raymond Joseph)

5.85%

Lowdell (Mark William)

5.68%

Moss (David J.)

4.84%

BlackRock Institutional Trust Company, N.A.

4.15%

The Vanguard Group, Inc.

3.60%

Other

75.89%

Shareholder Types

Shareholders

Proportion

Individual Investor

17.01%

Investment Advisor

11.65%

Investment Advisor/Hedge Fund

4.29%

Research Firm

0.95%

Venture Capital

0.18%

Hedge Fund

0.11%

Private Equity

0.09%

Bank and Trust

0.08%

Other

65.63%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

181

4.63M

17.40%

-3.18M

2025Q3

174

5.76M

21.67%

-1.34M

2025Q2

165

13.91M

52.32%

+314.04K

2025Q1

165

12.97M

59.27%

-484.99K

2024Q4

147

12.96M

58.46%

+804.75K

2024Q3

134

11.81M

53.27%

+318.25K

2024Q2

123

11.15M

54.62%

+1.47M

2024Q1

101

9.25M

51.52%

+199.50K

2023Q4

8.79M

48.95%

-237.73K

2023Q3

8.63M

48.03%

-362.72K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Tesi (Raymond Joseph)

1.55M

5.85%

Sep 30, 2025

Lowdell (Mark William)

1.51M

5.68%

Sep 30, 2025

Moss (David J.)

1.29M

4.84%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

1.10M

4.15%

+55.39K

+5.29%

Sep 30, 2025

The Vanguard Group, Inc.

876.29K

3.3%

+28.54K

+3.37%

Sep 30, 2025

Geode Capital Management, L.L.C.

469.44K

1.77%

+79.51K

+20.39%

Sep 30, 2025

State Street Investment Management (US)

283.83K

1.07%

+8.44K

+3.07%

Sep 30, 2025

Raymond James Financial Services Advisors, Inc.

253.50K

0.95%

-63.44K

-20.02%

Sep 30, 2025

Northern Trust Investments, Inc.

182.38K

0.69%

+19.92K

+12.26%

Sep 30, 2025

Susquehanna International Group, LLP

156.95K

0.59%

+137.01K

+686.93%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

iShares Micro-Cap ETF

0.01%

iShares Russell 2000 ETF

Fidelity Nasdaq Composite Index ETF

ProShares UltraPro Russell2000

Global X Russell 2000 ETF

ProShares Hedge Replication ETF

Proshares Ultra Russell 2000

Avantis US Small Cap Equity ETF

Dimensional US Core Equity 1 ETF

iShares Russell 2000 Growth ETF

iShares Micro-Cap ETF

Proportion0.01%

iShares Russell 2000 ETF

Proportion0%

Fidelity Nasdaq Composite Index ETF

Proportion0%

ProShares UltraPro Russell2000

Proportion0%

Global X Russell 2000 ETF

Proportion0%

ProShares Hedge Replication ETF

Proportion0%

Proshares Ultra Russell 2000

Proportion0%

Avantis US Small Cap Equity ETF

Proportion0%

Dimensional US Core Equity 1 ETF

Proportion0%

iShares Russell 2000 Growth ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data

KeyAI

